Spencer Phillips Hey
Spencer Hey, Ph.D.
Lecturer on Global Health and Social Medicine, Harvard Medical School
Temp Course Instructor, Harvard Medical School

Dr. Hey works on ethical, policy, and methodological issues at the intersection of philosophy of science and biomedical research ethics. He has published on a variety of topics, including the ethics of placebo-controlled trialsadaptive randomizationrisk minimization in early-phase human trialsdiscordant evidence, complexity and coordination problems in cancer biomarker research, and why clinical investigators ought to make explicit likelihood predictions in their research protocols. He has also developed a graph-theoretic approach to representing medical research programs. Published examples of the approach thus far have included research programs in tuberculosis and diagnostic development in precision medicine, but more examples--particularly in cancer drug development--will be appearing in print soon.

Dr. Hey received his Ph.D. in philosophy from the University of Western Ontarioand a B.A. in philosophy from the University of Illinois at Chicago. He is currently a faculty member at the Harvard Center for Bioethics and a research fellow in the Department of Medicine and the Division of Pharmacoepidemiology & Pharmacoeconomics at the Brigham and Women's Hospital. He previously held a research fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at the University of Oxford.

Publications View
The evidence landscape in precision medicine.
Authors: Authors: Hey SP, Gerlach CV, Dunlap G, Prasad V, Kesselheim AS.
Sci Transl Med
View full abstract on Pubmed
Research ethics for emerging trial designs: does equipoise need to adapt?
Authors: Authors: Hey SP, Weijer C, Taljaard M, Kesselheim AS.
View full abstract on Pubmed
Ethical Challenges in Biomarker-Driven Drug Development.
Authors: Authors: Hey SP.
Clin Pharmacol Ther
View full abstract on Pubmed
Is the concept of clinical equipoise still relevant to research?
Authors: Authors: Hey SP, London AJ, Weijer C, Rid A, Miller F.
View full abstract on Pubmed
Priority, prediction and the ethical research enterprise.
Authors: Authors: Hey SP.
J Med Ethics
View full abstract on Pubmed
Influence, integrity, and the FDA: An ethical framework.
Authors: Authors: Hey SP, Cohen IG, Adashi EY, Kesselheim AS.
View full abstract on Pubmed
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Authors: Authors: Hey SP, Franklin JM, Avorn J, Kesselheim AS.
Circ Cardiovasc Qual Outcomes
View full abstract on Pubmed
Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations.
Authors: Authors: Hey SP, Kesselheim AS.
Hastings Cent Rep
View full abstract on Pubmed
The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing.
Authors: Authors: Barsanti-Innes B, Hey SP, Kimmelman J.
View full abstract on Pubmed
Do We Know Whether Researchers and Reviewers are Estimating Risk and Benefit Accurately?
Authors: Authors: Hey SP, Kimmelman J.
View full abstract on Pubmed

Clinical trial participants should have a say in new drug pricing
By Spencer Phillips Hey
Stat News. May 18, 2017

Spencer Phillips Hey and Brianna Barsanti-Innes. "Epistemology, Ethics, and Progress in Precision Medicine." Perspectives in Biology and Medicine 59, no. 3 (2016): 293-310. https://muse.jhu.edu/